Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-05-26

Clinical Trial Update: Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of sorafenib in patients with metastatic renal cell carcinoma has completed; sponsored by the Egyptian Foundation For Cancer Research.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nexavar (Sorafenib)

Snippet

Sponsor: Egyptian Foundation For Cancer Research | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED